bilateral breast carcinoma
bilateral breast carcinoma
Explore linked clinical trials. Standard reference: MONDO:00039823 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, bilateral breast carcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 1 | 2026-07-31 | NCT04052555 | |
| Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, Unilateral Breast Neoplasms, bilateral breast carcinoma, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-06-30 | NCT03012100 | |
| Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | bilateral breast carcinoma, invasive breast carcinoma | Active, not recruiting | Phase 2 | 2026-05-22 | NCT00877500 |